SCHEMBL31326318

SCHEMBL31326318

Fc1cnc2[nH]cc(CCNCc3ccccc3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 3/20 0.57
▸ HTR6 P50406 3/20 0.57
▸ MPO P05164 3/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ HTR1A P08908 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ DRD2 P14416 1/20 0.57
▸ HTR7 P34969 1/20 0.57
▸ SLC6A4 P31645 1/20 0.57
▸ HRH4 Q9H3N8 1/20 0.45
▸ SNCA P37840 1/20 0.45
▸ MC5R P33032 2/20 0.44
▸ MC3R P41968 2/20 0.44
▸ MC1R Q01726 2/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ HDAC1 Q13547 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31326314 0.90 HTR6 (0.55) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL31326349 0.86 CYP3A4 (0.56) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL31326350 0.84 KMT2A (0.64) HTR2AHTR6CYP3A4HTR1ACYP2D6
SCHEMBL31326369 0.82 KMT2A (0.53) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL31326342 0.80 HTR6 (0.52) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL2405136 0.80 MPO (0.86) HTR2AHTR6MPOHTR1ASLC6A4
SCHEMBL31326334 0.78 HTR6 (0.49) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL31326353 0.76 HTR1A (0.55) HTR2AHTR6MPOCYP3A4HTR1A
Hydrochloric Acid SCHEMBL31635991 0.75 HTR1A (0.54) HTR2AHTR6MPOCYP3A4HTR1A
SCHEMBL25297431 0.74 CYP3A4 (0.46) HTR2AHTR6MPOCYP3A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735441-A1 PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES Psylo Pty Ltd (AU) 2026-05-06 — — EP disclosed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 — — US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 — — US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 — — US disclosed
WO-2025000051-A1 PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES Psylo Pty Ltd (AU) 2025-01-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB HTR2A 94/4885HTR6 54/4885MPO 559/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A HTR2A 3/4885HTR6 2/4885MPO 2816/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 HTR2A 2/4885HTR6 3/4885MPO 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback